

To submit a new prescription via eRx, use NPI 1902298805. Faxed prescriptions will only be accepted from prescribing practitioners. Patients may not submit prescriptions via fax and must submit original copies in person or via the mail. Prescribers are reminded patients may choose any pharmacy of their choice.

|   |  |
|---|--|
| <b>PATIENT INFORMATION</b>  | Patient: _____ Caregiver: _____  |
|   | DOB: _____ <input type="checkbox"/> Male <input type="checkbox"/> Female Weight: _____ <input type="checkbox"/> kgs or <input type="checkbox"/> lbs (check one) Height _____ <input type="checkbox"/> in or <input type="checkbox"/> cm (check one) Recorded Date: _____ |
|   | Address: _____ City: _____ State: _____ Zip: _____   |
|   | Best Phone #: _____ <input type="checkbox"/> Cell Alternate Phone #: _____ <input type="checkbox"/> Cell Email: _____  |
|   | Allergies: _____ Latex Allergy: <input type="checkbox"/> Yes <input type="checkbox"/> No   |
| ICD-10 Code for requested therapy: _____ ICD-10 Code(s) for other medical conditions: _____ |  |

**PLEASE FAX COPY OF ALL INSURANCE CARDS (FRONT & BACK) INCLUDING MEDICAL AND PRESCRIPTION**

|                           |  |  |                           |                                |
|---------------------------|--|--|---------------------------|--------------------------------|
| <b>MEDICAL ASSESSMENT</b> | <b>PRIOR HISTORY:</b>  | <b>PRIOR BIOLOGIC USE:</b>   | <b>DATE OF LAST DOSE:</b> | <b>PRIOR (FAILED) THERAPY:</b> |
|                           | <input type="checkbox"/> 5-ASA<br><input type="checkbox"/> Immunosuppressants (6-MP or other)<br><input type="checkbox"/> Corticosteroids<br><input type="checkbox"/> Methotrexate<br><input type="checkbox"/> Surgery<br><input type="checkbox"/> Other _____ | <input type="checkbox"/> Remicade®<br><input type="checkbox"/> Humira®<br><input type="checkbox"/> Cimzia®<br><input type="checkbox"/> Other _____ | _____                     | _____                          |

**PLEASE PROVIDE ALL CLINICAL INFORMATION INCLUDING LAB RESULTS ON ALL FORMS**

| <b>PRESCRIPTION INFORMATION</b> | <b>MEDICATION</b>  | <b>DOSE/STRENGTH</b>   | <b>DIRECTIONS</b>  | <b>QUANTITY</b>  | <b>REFILLS</b> |
|---------------------------------|--|--|--|--|----------------|
| <b>PREScription INFORMATION</b> | <b>Humira®</b><br>(adalimumab)   | <u>Starter Dose:</u><br><input type="checkbox"/> 6 x 40mg/0.8ml.   | <input type="checkbox"/> 160 mg Sub-Q Day 1, 80 mg Day 15, 40 mg Day 29 and every other week thereafter  | <input type="checkbox"/> 1 Kit = 6 x 40 mg Pens<br><input type="checkbox"/> 3 Cartons = 6 x 40 mg PFS  | 0              |
|                                 | <input type="checkbox"/> Enroll in Humira® Complete  | <u>Maintenance Dose:</u><br><input type="checkbox"/> 40 mg Pens<br><input type="checkbox"/> 40 mg Prefilled Syringes (PFS)   | <input type="checkbox"/> 40 mg Sub-Q every other week<br><input type="checkbox"/> 40 mg Sub-Q once weekly  | <input type="checkbox"/> 1 Carton = 2 x 40 mg Pens<br><input type="checkbox"/> 1 Carton = 2 x 40 mg PFS<br><input type="checkbox"/> 2 Cartons = 4 x 40 mg Pens<br><input type="checkbox"/> 2 Cartons = 4 x 40 mg PFS | _____          |
|                                 | <b>Entyvio®</b><br>(vedolizumab)   | <input type="checkbox"/> 300mg Single Use Vial   | <u>Starter Dose:</u><br><input type="checkbox"/> Infuse 300 mg intravenously over 30 minutes at week 0, 2, and 6   | 3 Vials  | 0              |
|                                 | <input type="checkbox"/> Enroll in EntyvioConnect  |  | <u>Maintenance Dose:</u><br><input type="checkbox"/> Infuse 300 mg intravenously over 30 minutes every 8 weeks   | 1 Vial   | _____          |
| <b>PREScription INFORMATION</b> | <b>Stelara®</b><br>(ustekinumab)   | <u>Starter Dose IV:</u><br><input type="checkbox"/> 2 Vials of 130 mg/26 mL IV<br><input type="checkbox"/> 3 Vials of 130 mg/26 mL IV<br><input type="checkbox"/> 4 Vials of 130 mg/26 mL IV | <input type="checkbox"/> 55 kg or less – Infuse 260 mg single dose over at least 1 hour<br><input type="checkbox"/> 56 kg to 85 kg – Infuse 390 mg single dose over at least 1 hour<br><input type="checkbox"/> more than 85 kg – Infuse 520 mg single dose over at least 1 hour | <input type="checkbox"/> _____ Total amount of single use vials  | 0              |
|                                 | <input type="checkbox"/> Enroll in CarePath®   | <u>Maintenance Dose:</u><br>90 mg Prefilled Syringe  | <input type="checkbox"/> Inject 90 mg SQ 8 weeks after the initial IV starter dose <b>then</b><br><input type="checkbox"/> 90 mg every 8 weeks thereafter  | 90 mg Prefilled Syringe<br>Qty: _____  | _____          |
| <b>PREScription INFORMATION</b> | <b>Remicade®</b><br>(infliximab)   | <input type="checkbox"/> 100 mg Lyophilized Vials (LYO)  | <u>Starter Dose:</u><br><input type="checkbox"/> 5 mg/kg IV at weeks 0, 2 and 6  | <input type="checkbox"/> _____ Vial(s)   | 0              |
|                                 | <input type="checkbox"/> Inflectra<br><input type="checkbox"/> Renflexis<br><input type="checkbox"/> Enroll in CarePath® |  | <u>Maintenance Dose:</u><br><input type="checkbox"/> 5 mg/kg IV every 8 weeks  | <input type="checkbox"/> _____ Vial(s)   | _____          |

|                                 |                                  | MEDICATION   | DOSE/STRENGTH   | DIRECTIONS   | QUANTITY  | REFILLS |
|---------------------------------|----------------------------------|--|---|--|---|---------|
| <b>PRESCRIPTION INFORMATION</b> | <b>Cimzia®</b><br>(certolizumab) | <input type="checkbox"/> Enroll in Cimzia® Connect   | <u>Starter Dose:</u><br><input type="checkbox"/> Cimzia Starter Kit (Prefilled Syringes)<br><input type="checkbox"/> 200 mg Lyophilized Vials (LYO) | <input type="checkbox"/> 400 mg Sub-Q at weeks 0, 2, and 4   | <input type="checkbox"/> 1 Kit = 6 x 200 mg/mL PFS<br><input type="checkbox"/> 3 Cartons = 6 x 200 mg Vials (LYO)   | 0       |
|                                 |                                  |  | <u>Maintenance Dose:</u><br><input type="checkbox"/> 200 mg/mL Prefilled Syringes<br><input type="checkbox"/> 200 mg Lyophilized Vials (LYO)        | <input type="checkbox"/> 400 mg Sub-Q every 4 weeks<br><input type="checkbox"/> 200 mg Sub-Q every 2 weeks | <input type="checkbox"/> 1 Carton = 2 x 200 mg/mL PFS<br><input type="checkbox"/> 1 Carton = 2 x 200 mg Vials (LYO) | _____   |
|                                 | <b>Simponi®</b><br>(golimumab)   | <input type="checkbox"/> Enroll in Janssen CarePath® | <u>Starter Dose:</u><br><input type="checkbox"/> 3 x 100mg/ml   | <input type="checkbox"/> Inject 200 mg SQ at week 0, <b>then</b> 100 mg at week 2                          | <input type="checkbox"/> SmartJext Autoinjector® <b>OR</b> <input type="checkbox"/> PFS                             | 0       |
|                                 |                                  |  | <u>Maintenance Dose:</u><br><input type="checkbox"/> 1 x 100mg/ml   | <input type="checkbox"/> Inject 100 mg SQ every 4 weeks  | <input type="checkbox"/> SmartJext Autoinjector® <b>OR</b> <input type="checkbox"/> PFS                             | _____   |
| <b>Other</b>                    |                                  |  |   |  |   |         |

**INJECTION TRAINING:**     **OFFICE TO COORDINATE**     **USSC TO COORDINATE**

|  |   |
|--|---|
| <b>PRESCRIBER INFORMATION</b>  | Anticipated Start Date: _____ Prescriber Specialty: _____   |
|  | Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Clinic <input type="checkbox"/> Other: _____  |
|  | Fax #: _____ Contact Name: _____  |
|  | Office Address: _____ City: _____ State: _____ Zip: _____   |
|  | The terms and conditions posted at <a href="http://www.usspecialtycare.com">www.usspecialtycare.com</a> have been read by the person signing this form and are incorporated into this document by reference. The data privacy terms posted at <a href="http://www.usspecialtycare.com">www.usspecialtycare.com</a> have been read by the person signing this form and are incorporated into this document by reference. |
|  | <input type="checkbox"/> I understand that USSC may transfer this prescription to another pharmacy as an agent of the prescriber if unable to dispense.   |
| Prescriber's Name: _____ Prescriber's Signature: _____ Date: _____                     |   |
| <input type="checkbox"/> Use substitution <input type="checkbox"/> Dispense as Written |   |

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling (800)-641-8475 to obtain instructions as to the proper destruction of the transmitted material.